Open an Account
search icon
1
NOTIFICATIONS
Best Algo trading app in India
Bigul

Glenmark Life Sciences Ltd - 543322 - Intimation Of Change Of Name Of The Registrar And Share Transfer Agent Of The Company From 'Kfin Technologies Private Limited' To 'Kfin Technologies Limited'

 We have been informed by the Registrar and Share Transfer Agent ("RTA") of the Company through email that pursuant to conversion of its status from private limited company to public limited company, its name has been changed from 'KFin Technologies Private Limited' to "KFin Technologies Limited".
15-03-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

 Pursuant to Regulation 32(6) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith Monitoring Agency Report issued by HDFC Bank Limited, Monitoring Agency, for the quarter ended 31st December, 2021 in respect of utilization of proceeds of the IPO of the Company. This is for your information and record.
14-02-2022

Earnings Call for Q3FY22 of Glenmark Life Sciences

 Conference Call with Glenmark Life Sciences Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
09-02-2022
Bigul

Q3FY22 Quarterly Result Announced for Glenmark Life Sciences Ltd.

 Pharmaceuticals company Glenmark Life Sciences declares Q3FY22 result: Glenmark Life Sciences reports revenue growth of 4.5% and PAT growth of 11.1% YoY for Q3 FY22 For the third quarter of FY22, GLS registered revenue from operations of Rs 5,225.0 Mn, recording a YoY growth of 4.5%. Revenues from the Generic API segment increased 0.9% YoY to Rs 4,714.6 Mn during the quarter whereas CDMO grew by 45.1% to Rs 405.7 Mn. During the quarter, revenues from the regulated markets witnessed healthy growth whereas revenues from the emerging markets were lower due to high base of COVID products sales last year Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) was at Rs 1,496.0 Mn for the third quarter with margin at 28.6%. Profit after Tax (PAT) was at Rs 1,037.1 Mn, registering a growth of 11.1% against the corresponding quarter of the previous financial year. For the nine months ended 31 Dec FY22, GLS registered revenue from operations of Rs 16,091.6 Mn, recording a YoY growth of 13.5%. Revenues from the Generic API segment increased 12.0% YoY to Rs 14,564.7 Mn whereas CDMO grew by 30.9% to Rs 1,285.0 Mn. Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) grew by 14.7% to Rs 4,834.6 Mn with margin at 30.0%. Profit after Tax (PAT) was at Rs 3,198.3 Mn, registering a growth of 29.5% against the same period last year. Commenting on the company’s performance Dr. Yasir Rawjee, MD & CEO, Glenmark Life Sciences Limited said, “At Glenmark Life Sciences we have delivered a steady performance in Q3FY22 with a healthy EBITDA margin. While the generic API business growth was muted due to the base effect of Covid API sales last year, we continued our strong momentum in the CDMO business fuelled by healthy demand and growth in the regulated markets. Our overall results reflect our operational resilience.” Dr. Rawjee further added, “The brownfield expansion for generic APIs at Dahej is well underway, which will substantially increase our capacity. We have also undertaken expansion at the Ankleshwar site to facilitate backward integration and the overall growth in demand. We also plan to commence the construction of a modern green-field manufacturing facility at Solapur, in the beginning of the next financial year. Going forward, we will continue to invest in expansion and in building our pipeline of products for sustainable long-term growth” Result PDF
09-02-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the investor presentation.
08-02-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2021

 Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2021. The said meeting of the Board commenced at 3.30 p.m. and concluded at 6.20 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith.
08-02-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Enclosed please find herewith the details of Earnings Call slated for Wednesday, February 9, 2022 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.
01-02-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Closure of Trading Window

 We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Tuesday, February 8, 2022, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2021. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from December 31, 2021 to February 10, 2022 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2021. The above is for your information.
31-01-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31, 2021.

 Glenmark Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2022 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2021.
31-01-2022
Bigul

Glenmark Life Sciences Ltd - 543322 - Shareholding for the Period Ended December 31, 2021

 Glenmark Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here
20-01-2022
Next Page
Close

Let's Open Free Demat Account